openPR Logo
Press release

High-Grade Glioma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Basilea Pharma, Erimos Pharma, Adastra Pharma, Chimerix, BioMimetix, Oblato, Inc.

10-24-2024 10:03 PM CET | Health & Medicine

Press release from: DelveIinsight Business Research

High-Grade Glioma Pipeline 2024: Clinical Trials Assessment,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, High-Grade Glioma pipeline constitutes 150+ key companies continuously working towards developing 150+ High-Grade Glioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"High-Grade Glioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.

Some of the key takeaways from the High-Grade Glioma Pipeline Report: https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years.
• High-Grade Glioma companies working in the treatment market are Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others, are developing therapies for the High-Grade Glioma treatment
• Emerging High-Grade Glioma therapies in the different phases of clinical trials are- ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.
• In April 2024, Denovo Biopharma LLC (Denovo), a leader in utilizing precision medicine for developing innovative treatments, has announced that the California Institute for Regenerative Medicine (CIRM) has granted $11.8 million for the continued advancement of DB107. This is Denovo's DGM7™ biomarker-guided late-stage gene therapy aimed at high-grade glioma (HGG), including glioblastoma (GBM), a type of malignant brain cancer. The grant has been awarded to Dr. Noriyuki Kasahara, MD, PhD, at the University of California San Francisco (UCSF), along with a team of researchers from California universities, to conduct a Phase 1/2 clinical trial evaluating DB107 in patients newly diagnosed with HGG.
• In November 2023, BioMimetix revealed that its BMX-001, when used alongside radiotherapy and temozolomide, extended the median survival period by 6.6 months among glioma patients. Additionally, the treatment showed promise in mitigating radiation-induced cognitive impairments and enhancing white matter integrity. These findings stem from the Phase II trial (NCT02655601) conducted by the clinical-stage biotech, focusing on the evaluation of BMX-001 in patients with high-grade glioma (HGG).
• In January 2023, "ONC201 for the Treatment of Newly Diagnosed H3 K27Mmutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study" is the name of the experiment that Chimerix started.
• In February 2023, According to Plus Therapeutics, the FDA is involved in the company's planned Investigational New Drug (IND) application for the treatment of pediatric patients with high-grade glioma and ependymoma.

High-Grade Glioma Overview
High-grade glioma (HGG) refers to a group of aggressive brain tumors that originate from glial cells, which provide support and protection for neurons. These tumors are classified as high-grade due to their rapid growth and tendency to invade surrounding brain tissue, making them difficult to treat. The most common type of HGG is glioblastoma multiforme (GBM), characterized by its heterogeneous cellular makeup and resistance to therapy. Symptoms of HGG can include headaches, seizures, cognitive changes, and neurological deficits, depending on the tumor's location in the brain. Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, but the prognosis remains poor, with limited survival rates.

Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:
• ONC201: Chimerix
• BMX-001: BioMimetix
• OKN-007: Oblato, Inc.
• Lisavanbulin: Basilea Pharmaceutica
• Terameprocol: Erimos Pharmaceuticals
• Zotiraciclib: Adastra Pharmaceuticals/S*Bio
• PTC596: PTC Therapeutics
• OS2966: OncoSynergy
• CAN 3110: Candel Therap
• DSP 0390: Sumitomo Pharma Oncology, Inc.
• Terameprocol: Erimos Pharmaceuticals
• Lenvatinib: Eisai Inc.
• PVSRIPO: Istari Oncology, Inc.
• BMX-001: BioMimetix Pharma

High-Grade Glioma Route of Administration
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

High-Grade Glioma Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types, such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

High-Grade Glioma Pipeline Therapeutics Assessment
• High-Grade Glioma Assessment by Product Type
• High-Grade Glioma By Stage and Product Type
• High-Grade Glioma Assessment by Route of Administration
• High-Grade Glioma By Stage and Route of Administration
• High-Grade Glioma Assessment by Molecule Type
• High-Grade Glioma by Stage and Molecule Type

DelveInsight's High-Grade Glioma Report covers around 150+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the High-Grade Glioma Therapeutics Market include:
Key companies developing therapies for High-Grade Glioma are - Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.

High-Grade Glioma Pipeline Analysis:
The High-Grade Glioma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.
• High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

High-Grade Glioma Pipeline Market Drivers
• Increasing the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.

High-Grade Glioma Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.

Scope of High-Grade Glioma Pipeline Drug Insight
• Coverage: Global
• Key High-Grade Glioma Companies: Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others
• Key High-Grade Glioma Therapies: ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others
• High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies
• High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers

Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. High-Grade Glioma Report Introduction
2. High-Grade Glioma Executive Summary
3. High-Grade Glioma Overview
4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment
5. High-Grade Glioma Pipeline Therapeutics
6. High-Grade Glioma Late Stage Products (Phase II/III)
7. High-Grade Glioma Mid Stage Products (Phase II)
8. High-Grade Glioma Early Stage Products (Phase I)
9. High-Grade Glioma Preclinical Stage Products
10. High-Grade Glioma Therapeutics Assessment
11. High-Grade Glioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. High-Grade Glioma Key Companies
14. High-Grade Glioma Key Products
15. High-Grade Glioma Unmet Needs
16 . High-Grade Glioma Market Drivers and Barriers
17. High-Grade Glioma Future Perspectives and Conclusion
18. High-Grade Glioma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

High-Grade Glioma Epidemiology https://www.delveinsight.com/report-store/high-grade-glioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'High-Grade Glioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release High-Grade Glioma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Basilea Pharma, Erimos Pharma, Adastra Pharma, Chimerix, BioMimetix, Oblato, Inc. here

News-ID: 3709134 • Views:

More Releases from DelveIinsight Business Research

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera Biosciences, Inc, Merck Sharp & Dohme LLC
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotech
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market. The PCSK9
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsight Report | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt, Cali Pharma
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Bunion

All 5 Releases


More Releases for Glioma

Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioma Competitive Landscape Report • DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market. Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187 The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioma Pipeline Report • DelveInsight's glioma pipeline report depicts a
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there